CD274 and neoplasm: The Impassion 130 trial used a cutoff of 91% tumor‐infiltrating immune cells with positive PD‐L1 staining and demonstrated a significantly longer OS of the atezolizumab plus nab‐paclitaxel group compared with the control group (25 vs. 18 months, HR = 0.71, 95% CI 0.54–0.94), which was not observed in intention‐to‐treat patients (HR = 0.86, 95% CI 0.72–1.02).5